Clinical trials: Alopecia Areata
Alopecia Areata
Assessment of Interleukin-15 and Interferon Gamma in Alopecia Areata Before and After Baricitinib.
The primary objective of this study was to evaluate the change in serum interferon gamma and Interleukin-15 levels before and after use of oral drug baricitinib therapy.
- Trial name
- Alopecia (NCT07645430)
- Testing
- Baricitinib 4 MG Oral Tablet
- Where
- Egypt
- Volunteers
- 20 people
- Sponsor
- Benha University
Severe Alopecia Areata
A Study to Learn About the Medicine Called Ritlecitinib in Adults With Severe Alopecia Areata in Real-world Settings
This study is a secondary analysis of the Adelphi Real World Alopecia Areata II United States Disease Specific Programmes database.
- Trial name
- NCT07200128
- Testing
- Ritlecitinib
- Where
- United States
- Volunteers
- 123 people
- Sponsor
- Pfizer
Alopecia Areata
A Study of LAD603 in Adults With Alopecia Areata
The main aim of the study is to evaluate the effect of LAD603 in adult participants with severe to very severe alopecia areata (AA).
- Trial name
- NCT07311564
- Testing
- LAD603
- Where
- United States
- Volunteers
- 136 people
- Sponsor
- Almirall, S.A.
Severe Alopecia Areata
A Study to Learn About Litfulo Capsule in People With Severe Alopecia Areata in Routine Clinical Practice.
The purpose of this observation study is to learn about the safety and effects of the study medicine (called Litfulo) for the potential treatment of Severe Alopecia Areata.
- Trial name
- NCT07152119
- Testing
- Litfulo
- Where
- South Korea
- Volunteers
- 3,000 people
- Sponsor
- Pfizer
Alopecia Areata
A Study of KL130008 in Adults With Severe Alopecia Areata
The purpose of this study is to assess KL130008 is safe and effective in adults with severe alopecia areata
- Trial name
- NCT05496426
- Where
- China
- Volunteers
- 114 people
- Sponsor
- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Alopecia Areata
A Phase 2a Proof-of-Concept Trial of Bempikibart (ADX-914) for the Treatment of Severe Alopecia Areata (SIGNAL-AA)
Part A is a randomized, double-blind, placebo-controlled, multi-center Proof-of-Concept (POC) Trial in subjects with severe Alopecia Areata. All participants in Part A have completed participation.
- Trial name
- SIGNAL-AA (NCT06018428)
- Testing
- bempikibart (ADX-914)
- Where
- 33 sites in United States, Canada
- Volunteers
- 75 people
- Sponsor
- Q32 Bio Inc.
Psoriasis, Alopecia Areata
Improving Disease Severity
Phototherapy, including ultraviolet B (UVB) and ultraviolet A (UVA) light, has been used to treat a number of dermatologic conditions.
- Conditions
- Psoriasis, Alopecia Areata, Polymorphous Light Eruption
- Trial name
- NCT05391178
- Testing
- Lumiton yarn sleeve, Lumiton yarn hat, Lumiton yarn shirt
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Wake Forest University Health Sciences
Healthy, Active Non-segmental Vitiligo
Study to Evaluate the Safety, Tolerability and How IBI3013 is Taken up and Processed by the Body in Healthy Volunteers After Single-dose Administration, and in Non-segmental Vitiligo Patients and Alopecia Areata Patients After Multiple-dose Administration
A multicenter clinical study to evaluate the safety, PK characteristics, immunogenicity characteristics, and PD characteristics of IBI3013 in healthy trial participants and active non-segmental vitiligo trial participants and…
- Conditions
- Healthy, Active Non-segmental Vitiligo, Severe Alopecia Areata
- Trial name
- NCT07554222
- Testing
- Baricitinib tablets, IBI3013
- Where
- China
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Alopecia Areata
A Study of Baricitinib (LY3009104) in Participants With Severe or Very Severe Alopecia Areata
This study is designed to select up to two doses of baricitinib (referred to as low dose and high dose) and assess their efficacy and safety for the treatment of severe or very severe alopecia areata.
- Trial name
- BRAVE-AA1 (NCT03570749)
- Testing
- Baricitinib
- Where
- 75 sites in United States, Japan and 3 more
- Volunteers
- 784 people
- Sponsor
- Eli Lilly and Company
Alopecia Areata
Safety and Efficacy of Oral NXC-736 in Adult Participants With Moderate and Severe Alopecia Areata
The purpose of this study is to evaluate the safety and efficacy of NXC-736 monotherapy in participants with severe alopecia areata (AA).
- Trial name
- NCT06104839
- Testing
- NXC736
- Where
- 2 sites in South Korea
- Volunteers
- 73 people
- Sponsor
- NEXTGEN Bioscience
Alopecia Areata
Long-Term PF-06651600 for the Treatment of Alopecia Areata
This is a global Phase 3 study to evaluate the safety and effectiveness of an investigational study drug (called PF-06651600) in adults and adolescents (12 years and older) who have alopecia areata.
- Trial name
- ALLEGRO-LT (NCT04006457)
- Testing
- PF-06651600, Tetanus and diphtheria toxoids and acellular pertussis (Tdap) vaccine, Meningococcal (groups A, C, W-135 and Y [ACWY]) oligosaccharide diphtheria CRM197 conjugate vaccine
- Where
- 144 sites in United States, Argentina and 15 more
- Volunteers
- 1,057 people
- Sponsor
- Pfizer
Alopecia Areata
A Study of Baricitinib (LY3009104) in Adults With Severe or Very Severe Alopecia Areata
The reason for this study is to see if baricitinib is safe and effective in adults with severe or very severe alopecia areata (AA).
- Trial name
- BRAVE-AA2 (NCT03899259)
- Testing
- Baricitinib
- Where
- 96 sites in United States, Argentina and 8 more
- Volunteers
- 606 people
- Sponsor
- Eli Lilly and Company
Alopecia Areata, Alopecia Areata(AA)
Association of Serum VEGF-A and VCAM-1 Levels With Nailfold Capilleroscopic Alterations in Alopecia Areata
The goal of this observational study is to learn about microvascular changes and hair follicle activity in patients with alopecia areata.
- Conditions
- Alopecia Areata, Alopecia Areata(AA), Alopecia Areata (AA)
- Trial name
- NCT07499713
- Testing
- Microvascular Imaging, Biochemical Biomarker Analysis, Trichoscopic Imaging
- Where
- Turkey (Türkiye)
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Istanbul Training and Research Hospital
Alopecia Areata
TREg Activation in the Treatment of the PELADE (Alopecia Areata)
In a prospective pilot study the investigators showed that low doses of IL2 could be beneficial for severe AA inducing a long lasting regrowth in 4 out of the 5 patients treated.
- Trial name
- TreatPelade (NCT02557074)
- Testing
- IL2
- Where
- 6 sites in France
- Volunteers
- 44 people
- Sponsor
- Centre Hospitalier Universitaire de Nice
Atopic Dermatitis, Alopecia Areata
A Longitudinal Observational Study of Patients Undergoing Therapy for IMISC
TARGET-DERM is a longitudinal, observational study of adult and pediatric patients being managed for Atopic Dermatitis and other Immune-Mediated Inflammatory Skin Conditions (IMISC) in usual clinical practice.
- Conditions
- Atopic Dermatitis, Alopecia Areata, Hidradenitis Suppurativa, Vitiligo
- Trial name
- TARGET-DERM (NCT03661866)
- Where
- 62 sites in United States, Canada and 2 more
- Volunteers
- 15,000 people
- Sponsor
- Target PharmaSolutions, Inc.
Alopecia Areata
Topical Methotrexate vs Minoxidil for Localized Alopecia Areata
Alopecia areata is an autoimmune disorder characterized by well-defined, non-scarring patches of hair loss on the scalp and other hair-bearing areas.
- Trial name
- MTX-MNX-AA (NCT07459933)
- Testing
- Methotrexate 1% Topical Gel, Minoxidil 5% Topical Spray
- Volunteers
- 268 people
- Sponsor
- Jinnah Postgraduate Medical Centre
Alopecia Areata, TLRs
Association of TLR7 Gene rs3853839 Polymorphism With Disease Severity in Alopecia Areata: A Case-Control Study
Alopecia areata is an autoimmune, non-scarring hair loss disorder characterized by variable clinical severity. Toll-like receptor 7 (TLR7) plays a key role in innate immune activation and autoimmune responses.
- Trial name
- TLR7-AA (NCT07454876)
- Where
- Egypt
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Benha University
Alopecia Areata(AA)
Impact of NR3C1 rs41423247 (BclI) Polymorphism on Disease Severity in Alopecia Areata
Alopecia areata is an autoimmune, non-scarring hair loss disorder with multifactorial pathogenesis. The glucocorticoid receptor gene (NR3C1) plays an essential role in immune regulation and inflammatory response.
- Trial name
- NR3C1 and AA (NCT07455708)
- Where
- Egypt
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Benha University
Alopecia Areata (AA)
A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of ALD-102 Solution in Subjects With Alopecia Areata
The goal of this first-in-human clinical trial is to learn if ALD-102 Solution is safe and well tolerated following injections in the scalp in subjects with alopecia areata.
- Trial name
- ARISE (NCT06826196)
- Testing
- ALD-102 Solution
- Where
- 7 sites in United States, Canada
- Volunteers
- 24 people
- Sponsor
- Aldena Therapeutics
Non-Segmental Vitiligo (NSV), Alopecia Areata
A Real World Study to Globally Assess Disease Burden in Adolescent and Adult Participants With Alopecia Areata, Vitiligo, or Hidradenitis Suppurativa
This study is to assess the burden of disease in adolescent and adult participants with moderate or severe alopecia areata (AA), non-segmental vitiligo (NSV), or moderate to severe hidradenitis suppurativa (HS) in a large global…
- Conditions
- Non-Segmental Vitiligo (NSV), Alopecia Areata, Hidradenitis Suppurativa
- Trial name
- MEASUREAAVitHS (NCT07136467)
- Where
- 116 sites in Argentina, Canada and 16 more
- Volunteers
- 2,795 people
- Sponsor
- AbbVie